Blueberry Therapeutics are delighted to welcome Heather Davies to the team as an Analytical Scientist. Heather is a biochemist by training and joins Blueberry after completing a post doc in France. She brings with her [...]
Alderley Park, UK, 4thDecember 2018– Blueberry Therapeutics won the coveted ‘Company of the Year’ award after another remarkable year of progress and innovation. 2018 has seen many great achievements for Blueberry Therapeutics including the [...]
Blueberry Therapeutics are delighted to welcome Noria Mbuisa to the team! Noria joins us as a Clinical Research Associate, where she leads the review of study regulatory documents and data analysis. Noria has a [...]
Blueberry Therapeutics would like to extend a warm welcome to Christian, who joins us with a wealth of experience as a Senior Clinical Project Manager. Christian has over 15 years’ experience in the pharmaceutical industry; [...]
Blueberry CEO, John Ridden, will be attending the 2nd Dermatology Drug Development Summit in Boston, 27-29th November 2018. The event is a unique industry-led conference focusing on innovating & accelerating the development amd commercialisation of dermatological [...]
Alderley Park, UK, 21stNovember 2018– Blueberry Therapeutics Limited (“Blueberry Therapeutics”), a modern drug discovery and development company committed to the development of innovative new therapies for the treatment of common and difficult to treat dermatological [...]
David Cook presented at the recent ELRIG (European Laboratory Research and Innovation group) Drug Discovery Conference. David was invited to present in a workshop called “Build Biotech Success: A practical case study with CROs at [...]
Alderley Park, UK, 14 August 2018– Blueberry Therapeutics Limited, (“Blueberry Therapeutics”) a drug discovery and development company focused on developing innovative nanomedicines for difficult to treat skin and nail infections, today announces that it [...]
John Ridden, Blueberry CEO will be attending BIO International convention in Boston, 4th-7th June. 2018 is the 25th year for the BIO Convention, and attracts more than 16,000 biotechnology and pharma leaders who come [...]
John Ridden, David Cook and Mark Hollingworth will be attending BioTrinity London 23-25 April. BioTrinity is Europe’s leading biopartnering and investment conference, and is in its 12thconsecutive year. The theme for 2018 is “Next Generation [...]
David presented at a recent Oxford Bio Network (OBN) BioTuesday Seminar, "De-risking the Valley of Death – How R&D Companies can access the Knowledge Network to Maximise Success” as part of a delegation from [...]
8th -11th of January 2018: CEO Dr. John Ridden has been invited to attend the J.P. Morgan 36th Annual Healthcare Conference in San Francisco, California. John will be presenting Blueberry to a number of prospective [...]
Blueberry Therapeutics CSO David Cook presents at the first Royal Society Creating Connections conference, Research, industry and infrastructure in the North West, at Manchester's Museum of Science and Industry. David was invited to speak at this exciting event, [...]
John Ridden, CEO of Blueberry Therapeutics, recently presented at the UK-China Life Science Event run by the DIT (Department for International Trade). The event was hosted by Lancaster University and is an opportunity for [...]
Blueberry Therapeutics Ltd is pleased to announce that it has taken a significant step forward in the development of new Acne treatments by gaining support from Innovate UK to co-fund critical research of this [...]
Blueberry Therapeutics CEO John Ridden presented at the Biofocus 2017 event at the Centre for Life in Newcastle upon Tyne as part of the Industry Showcase session. The Biofocus event is an annual event bringing [...]
Blueberry Scientists Sarah Main and Julie Cook, attended the “Kinetics, Binding and Biophysics in Drug Discovery” workshop at The Mechanics Centre, Manchester on 27th June 2017. Attending the workshop will assist in current and future assay [...]
CSO David Cook attended the European Mediscience Awards Dinner in London as a guest of Zeus Capital. The Mediscience Awards recognize excellence in the Life Science sector and are held annually.
CSO David Cook presented at the recent ELRIG (European Laboratory Research & Innovation Group) held at Alderley Park. David presented as part of a diverse evening of seminars on the topic “Novel Approaches to Meeting [...]
Blueberry Therapeutics are pleased to announce they have dosed the first patient in a Phase I/II clinical trial of BB2603 in fungal infection of the skin and nail following successful regulatory and ethics approvals. The [...]
